Pharma BD Deal Intelligence
GSK's $500M-upfront licensing deal for Hengrui's HRS-9821, a best-in-class PDE3/4 inhibitor for COPD, with an option structure covering up to 11 more respiratory, immunology, and oncology programs worth up to $12B in aggregate. It's a foothold play into China-originated pipeline assets rather than a control deal, though Hengrui retains development through Phase 1—leaving the real payoff contingent on GSK exercising options it hasn't yet triggered.
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
GSK will pay Hengrui $500 million upfront to start the alliance. In return, it will receive rights outside of the greater China region and Taiwan to an…
GSK said Monday it would pay $500 million upfront for rights to an experimental COPD drug from Jiangsu Hengrui Pharmaceuticals, the latest example of a pharma…
A Jefferies report found one-third of pharma licensing deal spending in H1 2025 involved China-originated drugs, up from 21% in prior years, raising…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
GSK licensed a potential best-in-class PDE3/4 inhibitor HRS-9821 for COPD from Hengrui Pharma, plus agreements to develop up to 11 additional programs across respiratory, immunology/inflammation, and oncology. GSK paid $500M upfront for the PDE3/4 program. Total potential value up to ~$12B if all programs are optioned and all milestones achieved. Hengrui leads development through Phase 1 completion.
16M US cases/yr · $23.5B Global COPD Drug Market (2025)
COPD affects approximately 16 million diagnosed Americans (with millions more undiagnosed) and is the 3rd leading cause of death in the US. The $23.5B global COPD drug market is dominated by inhaled corticosteroids, LABAs, and LAMAs, with the dual PDE3/4 inhibitor class representing the most significant new mechanism in decades.
GSK's $12B deal with Hengrui targets HRS-9821, a potential best-in-class PDE3/4 inhibitor in convenient DPI format, competing against Verona Pharma's approved Ohtuvayre (nebulizer formulation). GSK already dominates COPD with Trelegy/Breo/Nucala and sees HRS-9821 as the next-generation bronchodilator/anti-inflammatory to extend its respiratory leadership against AstraZeneca (Breztri) and Boehringer (Spiriva).
GSK licensed a potential best-in-class PDE3/4 inhibitor HRS-9821 for COPD from Hengrui Pharma, plus agreements to develop up to 11 additional programs across respiratory, immunology/inflammation, and oncology. GSK paid $500M upfront for the PDE3/4 program. Total potential value up to ~$12B if all pr
Hengrui began a Phase 1 study (NCT07116915) of HRS-9821 Powder for Inhalation in healthy subjects and COPD patients (start 2025-08-11; recruiting; est. primary completion Dec 2026), advancing the lead asset GSK licensed in the July 2025 collaboration.
Transaction between GSK plc and Jiangsu Hengrui Pharmaceuticals Co. Ltd. is pending completion. Assessment will be updated upon deal close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| GSK plc / Jiangsu Hengrui Pharmaceuticals Co. Ltd. (this deal) | 2025 | $12.0B | 65 |
| GSK plc / SmithKline Beecham | 2000 | $12.0B | 79 |
| GSK plc / Pfizer Inc. | 2018 | $0.0M | 77 |
| GSK plc / Novartis AG | 2014 | $16.0B | 76 |
| GSK plc / Hansoh Pharmaceutical Group Co. Ltd. | 2023 | $1.7B | 74 |
| GSK plc / Nuvalent, Inc. | 2026 | $10.6B | 70 |
| GSK plc / Sierra Oncology Inc. | 2022 | $1.9B | 70 |
← Browse all deals · How we score deals
More: 2025 deals · GSK plc deals · Respiratory deals